COMP and cancer: The involved mechanisms include NF-κB pathway inhibition [202], regulation of the miR-138-p5/Forkhead box C1 protein (FOXC1) pathway [203], MAPK pathway inhibition [204], modulation of macrophage polarization [205], cancer-associated fibroblasts-derived cartilage oligomeric matrix protein (COMP) inhibition [206], and reduced TNFα-induced c-Myc expression [207].